OM1 adds Rory O’Driscoll to its Board along with raising $50m Series C financing led by Scale Venture Partners

– USA, MA –  OM1, a real-world outcomes and technology company, today announced $50 million in Series C financing led by Scale Venture Partners, with participation from existing investors, including General Catalyst (GC), Polaris Partners, and 7wire Ventures.

In conjunction with the funding, Rory O’Driscoll, Partner at Scale Venture Partner, has joined OM1′s Board of Directors.

“AI and data are driving factors in the transformation of many industries,” said Driscoll. “OM1 is at the forefront of bridging these two in transformative ways in healthcare, and we are excited to be part of the journey to drive the better development of medicine and delivery of care.”

“Clinical outcomes are the most important metric in healthcare,” said Dr. Richard Gliklich, CEO and founder of OM1. “With this funding, OM1 will accelerate our work towards delivering rapid access to real-world outcomes and evidence and with helping our customers apply those data in impactful ways.”

Increasingly healthcare stakeholders, including regulators, payer and providers, are seeking real-world evidence for supporting outcomes-based decision making. By organizing health information and applying artificial intelligence (AI) technology, OM1 helps customers generate and use real-world evidence more rapidly and effectively to gain regulatory approval, understand the effectiveness, safety and value of treatments, and personalized care.

OM1 focuses on specific therapeutic areas, including chronic conditions like immunology, rheumatology, cardiometabolic disorders, musculoskeletal conditions and central nervous system (CNS)/behavioral health. Among the products developed by OM1 are industry-leading therapeutic-focused registries for advancing medical research, such as in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), and state-of-the-art AI solutions for measuring and predicting outcomes for patients and populations.

The funding comes on the heels of a high-growth year for OM1 in which the company has seen more than 400% growth in year-over-year sales. OM1 will use the funding to continue the buildout of its data-driven solutions for real-world evidence, value-based care, and predictive medicine.

About OM1

OM1 was founded in 2015 by Dr. Richard Gliklich, an Executive-in-Residence (XIR) at GC and the former founder of Outcome, a technology and services company focused on real-world research and health outcomes that was acquired in 2011. Dr. Gliklich is also the principal investigator for a major federal effort focused on outcomes measurement and standardization.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.